We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer.
- Authors
Hoffman, Richard M.; Koyama, Tatsuki; Kang-Hsien Fan; Albertsen, Peter C.; Barry, Michael J.; Goodman, Michael; Hamilton, Ann S.; Potosky, Arnold L.; Stanford, Janet L.; Stroup, Antoinette M.; Penson, David F.
- Abstract
Background No randomized trials have compared survival outcomes for men with localized prostate cancer (PC) being treated with radical prostatectomy (RP) or external beam radiotherapy (EBRT). The goal of the study, therefore, was to estimate the association of RP (compared with EBRT) with overall and PC mortality. Methods We analyzed an observational cohort from the population-based Prostate Cancer Outcomes Study, which included men aged 55 to 74 years diagnosed with localized PC between October 1994 and October 1995 who underwent either RP (n = 1164) or EBRT (n = 491) within 1 year of diagnosis. Patients were followed until death or study end (December 31, 2010). Overall and disease-specific mortality were assessed with multivariable survival analysis, with propensity scores to adjust for potential treatment selection confounders (demographics, comorbidities, and tumor characteristics). All statistical tests were two-sided. Results After 15 years of follow-up, there were 568 deaths, including 104 from PC. RP was associated with statistically significant advantages for overall (hazard ratio [HR] = 0.60, 95% confidence interval [CI] = 0.53 to 0.70, P<.0001.) and disease-specific mortality (HR = 0.35, 95% CI = 0.26 to 0.49, P <.0001.). Mortality benefits for RP were also observed within treatment propensity quintiles, when subjects were pair-matched on propensity scores, and in subgroup analyses based on age, tumor characteristics, and comorbidity. Conclusions Population-based observational data on men diagnosed with localized PC in the mid-1990s suggest a mortality benefit associated with RP vs EBRT. Possible explanations include residual selection bias or a true survival advantage. Results might be less applicable for men facing treatment decisions today.
- Subjects
PROSTATECTOMY; PROSTATE cancer treatment; CANCER radiotherapy research; PROSTATE surgery; CANCER-related mortality
- Publication
JNCI: Journal of the National Cancer Institute, 2013, Vol 105, Issue 10, p711
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djt059